Therefore, erlotinib (Figure 16), an important EGFR inhibitor, in particular for the treatment of EGFR mutated advanced or metastatic non-small-cell lung carcinoma (NSCLC), was tested on SOD1G93A mice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.